Literature DB >> 35925331

[Multimodal imaging of a unilateral reddish iris lesion].

Philomena A Wawer Matos1, Alexander C Rokohl2, Alexandros Doulis2, Michael Simon2, Sarah Zwingelberg2, Sigrid Roters2, Ludwig M Heindl2,3.   

Abstract

Entities:  

Year:  2022        PMID： 35925331     DOI： 10.1007/s00347-022-01654-y

Source DB:  PubMed          Journal:  Ophthalmologie        ISSN： 2731-720X


× No keyword cloud information.
  8 in total

1.  [Unilateral tumor of the iris].

Authors:  A Ammermann; H Platzeck; H Hoerauf
Journal:  Ophthalmologe       Date:  2011-02       Impact factor: 1.059

2.  Surgical management for large hypertropia and exotropia after disinsertion of inferior rectus muscle.

Authors:  Samin Hong; Seung Jae Lee; Hyung Keun Lee; Gong Je Seong; Sueng-Han Han
Journal:  Ophthalmic Surg Lasers Imaging       Date:  2008 Nov-Dec

3.  Recurrent systemic B cell lymphoma of the iris.

Authors:  P G Hykin; J A Shields; C L Shields; H Ehya; E Siderides
Journal:  Br J Ophthalmol       Date:  1996-10       Impact factor: 4.638

4.  Optical Coherence Tomography Angiography Features of Iris Racemose Hemangioma in 4 Cases.

Authors:  Jason L Chien; Kareem Sioufi; Sandor Ferenczy; Emil Anthony T Say; Carol L Shields
Journal:  JAMA Ophthalmol       Date:  2017-10-01       Impact factor: 7.389

5.  Arteriovenous communication of the iris.

Authors:  M Prost
Journal:  Br J Ophthalmol       Date:  1986-11       Impact factor: 4.638

Review 6.  The phakomatoses.

Authors:  R L Font; A P Ferry
Journal:  Int Ophthalmol Clin       Date:  1972

7.  CyberKnife radiosurgery for the treatment of intraocular and periocular lymphoma.

Authors:  Carlos Bianciotto; Carol L Shields; Sara E Lally; Jorge Freire; Jerry A Shields
Journal:  Arch Ophthalmol       Date:  2010-12

8.  Solitary idiopathic choroiditis: findings on enhanced depth imaging optical coherence tomography in 10 cases.

Authors:  Adrian T Fung; Swathi Kaliki; Carol L Shields; Arman Mashayekhi; Jerry A Shields
Journal:  Ophthalmology       Date:  2012-12-12       Impact factor: 12.079
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.